The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature

Conclusion: Considering their pharmacological properties, their efficacy and bleeding complications, the new oral agents offer a net favourable clinical profile in orthopedic surgery, atrial fibrillation, acute coronary syndrome and increase the risk of bleeding in critically ill patients. Further studies are necessary to determine the long term safety and to identify the specific reversal agents of these new drugs.
Source: Thrombosis Journal - Category: Hematology Authors: Source Type: research